Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Profit After Tax (2016 - 2025)

Historic Profit After Tax for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to -$651482.0.

  • China Pharma Holdings' Profit After Tax rose 4172.33% to -$651482.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.2 million, marking a year-over-year increase of 3245.82%. This contributed to the annual value of -$4.7 million for FY2024, which is 5383.71% down from last year.
  • Per China Pharma Holdings' latest filing, its Profit After Tax stood at -$651482.0 for Q3 2025, which was up 4172.33% from -$528367.0 recorded in Q2 2025.
  • China Pharma Holdings' 5-year Profit After Tax high stood at -$475976.0 for Q1 2023, and its period low was -$1.4 million during Q2 2024.
  • For the 5-year period, China Pharma Holdings' Profit After Tax averaged around -$903544.7, with its median value being -$826669.0 (2021).
  • Its Profit After Tax has fluctuated over the past 5 years, first crashed by 641855.51% in 2021, then skyrocketed by 6326.01% in 2025.
  • Over the past 5 years, China Pharma Holdings' Profit After Tax (Quarter) stood at -$980719.0 in 2021, then dropped by 28.9% to -$1.3 million in 2022, then increased by 2.53% to -$1.2 million in 2023, then increased by 0.63% to -$1.2 million in 2024, then soared by 46.79% to -$651482.0 in 2025.
  • Its Profit After Tax stands at -$651482.0 for Q3 2025, versus -$528367.0 for Q2 2025 and -$800000.0 for Q1 2025.